The Vienna-based firm will use the funding to support the ongoing validation of its Aitios assay in collaboration with the Fetal Medicine Research Institute.
The biotech has reached agreement with the agency to continue enrollment in a pivotal Phase II trial of RP-A501, which was ...
The Shenzen-based sequencing technology company plans to use the money to boost its R&D for multiomics technologies and fuel ...
The patents at issue involve methods involving the bisulfite conversion of cell-free DNA from a blood-derived sample, ...
BBB National Programs’ National Advertising Division asked controversial startup Nucleus Genomics to stop using certain ...
The FDA has granted priority review to Intellia’s biologics license application for lonvo-z and plans to issue a decision by March 10, 2027.
The accelerated approval was based on results from the Phase I/II SOHO-01 trial showing a 75 percent response rate to ...
The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.
The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share, noting their strong positions in non-oncology markets and recent moves into cancer testing.
New products for the week of Sept. 7, 2026: Google, BGI Genomics, and Helix.
Google DeepMind has launched AlphaGenome Atlas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results